Volume 28, Number 6—June 2022
Research
Effect of Recombinant Vesicular Stomatitis Virus–Zaire Ebola Virus Vaccination on Ebola Virus Disease Illness and Death, Democratic Republic of the Congo
Neil Rupani
, Mbong Eta Ngole, J. Austin Lee, Adam R. Aluisio, Monique Gainey, Shiromi M. Perera, Lina Kashibura Ntamwinja, Ruffin Mbusa Matafali, Rigo Fraterne Muhayangabo, Fiston Nganga Makoyi, Razia Laghari, Adam C. Levine, and Alexis S. Kearney
, Mbong Eta Ngole, J. Austin Lee, Adam R. Aluisio, Monique Gainey, Shiromi M. Perera, Lina Kashibura Ntamwinja, Ruffin Mbusa Matafali, Rigo Fraterne Muhayangabo, Fiston Nganga Makoyi, Razia Laghari, Adam C. Levine, and Alexis S. Kearney
Table 1
Patient characteristics for study of the effect of recombinant vesicular stomatitis virus–Zaire Ebola virus vaccination on Ebola virus disease illness and death, Democratic Republic of the Congo*
| Characteristic | Overall, n = 385 | Not vaccinated, n = 248 | Vaccinated, n = 137 | p value† |
|---|---|---|---|---|
| Age, y | 26.0 (18.0‒40.0) | 25.5 (12.0‒40.0) | 28.0 (20.0‒40.0) | 0.044 |
| <5 | 49 (12.7) | 43 (17.3) | 6 (4.4) | 0.001 |
| 5‒15 | 34 (8.8) | 26 (10.5) | 8 (5.8) | |
| 16‒25 | 101 (26.2) | 55 (22.2) | 46 (33.6) | |
| 26‒35 | 88 (22.9) | 54 (21.8) | 34 (24.8) | |
| 36‒45 | 38 (9.9) | 19 (7.6) | 19 (13.9) | |
| 46‒55 | 41 (10.7) | 27 (10.9) | 14 (10.2) | |
| >55 |
34 (8.8) |
24 (9.7) |
10 (7.3) |
|
| Sex | 0.018 | |||
| M | 159 (41.3) | 91 (36.7) | 68 (49.6) | |
| F |
226 (58.7) |
157 (63.3) |
69 (50.4) |
|
| Province | 0.002 | |||
| North Kivu | 235 (61.0) | 142 (57.3) | 93 (67.9) | |
| Ituri | 142 (36.9) | 104 (41.9) | 38 (27.7) | |
| Unknown |
8 (2.1) |
2 (0.8) |
6 (4.4) |
|
| Known or suspected Ebola contact | <0.001 | |||
| No | 73 (19.0) | 62 (25.0) | 11 (8.0) | |
| Yes | 220 (57.1) | 130 (52.4) | 90 (65.7) | |
| Unknown |
92 (23.9) |
56 (22.6) |
36 (26.3) |
|
| Days between symptom onset and admission, d |
4.0 (2.0‒6.0) |
5.0 (3.0‒7.0) |
2.0 (1.0‒4.0) |
<0.001 |
| First cycle threshold value |
21.6 (18.2‒26.2) |
20.4 (17.7‒24.2) |
24.6 (19.9‒28.1) |
<0.001 |
| Therapeutic received | 0.005 | |||
| None | 65 (16.9) | 53 (21.4) | 12 (8.8) | |
| Zmapp or Remdesivir | 76 (19.7) | 46 (18.5) | 30 (21.9) | |
| mAb114 or REGN-EB3 |
244 (63.4) |
149 (60.1) |
95 (69.3) |
|
| Final outcome | <0.001 | |||
| Died | 191 (49.6) | 157 (63.3) | 34 (24.8) | |
| Survived |
194 (50.4) |
91 (36.7) |
103 (75.2) |
|
| Length of stay among survivors, d | 21.0 (18.0‒26.0), n = 193 | 22.0 (19.0‒28.5), n = 91 | 20.0 (17.0‒23.8), n = 102 | 0.004 |
*Values are median (IQR) or no. (%) . IQR, interquartile range; MAb, monoclonal antibody. †Statistical tests were performed by using the Wilcoxon rank sum test, the Pearson χ2 test, and the Fisher exact test. Boldface indicates a significant difference (p<0.05).
Page created: March 31, 2022
Page updated: May 22, 2022
Page reviewed: May 22, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.